Sagimet Biosciences Balance Sheet Health
Financial Health criteria checks 6/6
Sagimet Biosciences has a total shareholder equity of $170.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $174.8M and $4.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$152.49m |
| Equity | US$170.68m |
| Total liabilities | US$4.09m |
| Total assets | US$174.78m |
Recent financial health updates
Recent updates
Sagimet: More Than Just A MASH Drug Development Biotech
Nov 14Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat
Oct 18Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide
Jul 31Companies Like Sagimet Biosciences (NASDAQ:SGMT) Are In A Position To Invest In Growth
May 31
Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity
Apr 26Sagimet: Additional Upside Possible After Latest NASH Data Release
Jan 24Financial Position Analysis
Short Term Liabilities: SGMT's short term assets ($157.2M) exceed its short term liabilities ($4.1M).
Long Term Liabilities: SGMT has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: SGMT is debt free.
Reducing Debt: SGMT has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SGMT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: SGMT has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 18.2% each year